SLC39A7 and central nervous system cancer: To further confirm whether SLC39A7 promotes the proliferation, invasion and migration of glioma cells by activating TNF-α, SLC39A7-overexpressing U87 and LN229 cells were treated with QNZ (EVP4593), a TNF-α inhibitor.